Oxidative stress ups POAG risk

Article

Oxidative stress may play a role in the pathogenesis of primary open angle glaucoma (POAG), according to a study published in the June/July 2008 issue of the Journal of Glaucoma.

Oxidative stress may play a role in the pathogenesis of primary open angle glaucoma (POAG), according to a study published in the June/July 2008 issue of the Journal of Glaucoma.

Vicente Zanon-Moreno, BS of the Ophthalmologic Research Unit Santiago Grisolia, Dr Peset University Hospital, Valencia, Spain and colleagues conducted a case control study of eyes undergoing antiglaucomatous surgery for POAG (n=50) and for nonpathologic cataracts (n=40) to determine the antioxidant status of the aqueous humour. The research team tested free radical formation via lipid peroxidation by malondialdehyde-thiobarbituric acid reactive substances (MDA-TBARS) and conducted statistical analysis to see how these related to glaucoma risk.

When compared with the cataract patients, POAG subjects had significantly higher levels of MDA-TBARS and significantly lower levels of antioxidant activity.

As the glaucomatous eyes showed higher levels of oxidative stress in the aqueous humour than did the control group of cataract eyes, the researchers concluded that oxidative stress may be associated with the development of POAG.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.